7-Benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-3-carbaldehyde

Catalog No.: 
ACLKIO971
CAS No.: 
165894-25-7
Molecular Formula: 
C14H15N3O
Molecular Weight: 
241.29
7-Benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-3-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$313.00InquiryInquiry
250mg95%$720.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-Benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-3-carbaldehyde
IUPAC Name7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-3-carbaldehyde
MDL No.MFCD22573751
Molecular FormulaC14H15N3O
Molecular Weight241.29
SMILESO=CC1=NC=C2CN(CC3=CC=CC=C3)CCN21
InChI KeySNLVADHMLFZLHT-UHFFFAOYSA-N
Synonym7-BENZYL-5,6,7,8-TETRAHYDROIMIDAZO[1,5-A]PYRAZINE-3-CARBALDEHYDE;Imidazo[1,5-a]pyrazine-3-carboxaldehyde, 5,6,7,8-tetrahydro-7-(phenylmethyl)-
CAS No.165894-25-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACLKIO971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLKIO971 route product structure diagram
    ACLKIO971165894-25-7
Inquiry

2. ACLKIO971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLKIO971 route product structure diagram
    ACLKIO971165894-25-7
Inquiry

3. ACLKIO971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLKIO971 route product structure diagram
    ACLKIO971165894-25-7
Inquiry

Comments (0)